SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-009396
Filing Date
2022-05-26
Accepted
2022-05-26 16:15:12
Documents
12
Period of Report
2022-05-26
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K sgtx-20220526x8k.htm   iXBRL 8-K 53452
  Complete submission text file 0001558370-22-009396.txt   178040

Data Files

Seq Description Document Type Size
2 EX-101.SCH sgtx-20220526.xsd EX-101.SCH 3031
3 EX-101.LAB sgtx-20220526_lab.xml EX-101.LAB 16735
4 EX-101.PRE sgtx-20220526_pre.xml EX-101.PRE 10609
6 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20220526x8k_htm.xml XML 5053
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39746 | Film No.: 22970165
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences